Exhibit 99.1 X XENON Xenon Reports Q2 2024 Financial Results and Business Update – Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 – MDD program on track with Phase 3 study expected to initiate in H2 2024 – Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia, August 8, 2024 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurosciencefocused biopharmaceutical com ...

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: | --- | --- | |----------------|----------------------------- ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and CEO Dr. Chris Kenney - Chief Medical Officer Dr. Chris Von Seggern - Chief Commercial Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Leo Timashev - RBC Capital Markets Jason Gerberry - Bank of America Luke Hermann - Baird Tess Romero - JPMorgan Khalil Fenina - Gold ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Canada 98-0661854 ...

Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful "end-of-Phase 2" interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript February 29, 2024 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Chris Kenney - CMO Chris Von Seggern - CCO Conference Call Participants Paul Matteis - Stifel Leonid Timashev - RBC Capital Markets Tess Romero - JPMorgan Andrew Tsai - Jefferies Danielle Brill - Raymond James Joseph Thome - TD Cowen Brian Skorney - Baird Marc Goodman - Leerink Partners Laura Chico - Wedbush Security Operator Good aft ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisdictio ...

Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025 Planned "end-of-Phase 2" meeting with the FDA in April to support the initiation of XEN1101 Phase 3 program in major depressive disor ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Danielle Brill - Raymond James ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-066 ...